Disc Medicine, Inc. (IRON): Results of Operations and Financial Condition
Disc Medicine, Inc. (IRON) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 iron-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update • Completed Type A meeting with the FDA on bitopertin and aligned that the Phase 3 APOLLO study, if successful, can serve as the basis f
How this was made
The 30-second read
Why it matters
Traders can update probability-weighted expectations for bitopertin’s registrational pathway based on the completed FDA Type A meeting and the stated timing for APOLLO topline and CRL response decision.
Market read
The combination of FDA pathway alignment, specific upcoming clinical data timing, and a cash runway into 2029 provides actionable milestone re-pricing for IRON.
What to watch
The filing does not provide new APOLLO efficacy results, and the net loss and rising operating costs highlight ongoing burn despite the cash runway.
Background
This SEC 8-K (Item 2.02) accompanies Disc Medicine’s Q2 2026 financial results and a program/business update across bitopertin, selcodebart, and DISC-3405.
Ticker impact
Disc Medicine reports Q2 2026 cash of about $717.7M and updates that APOLLO bitopertin topline is expected in Q4 2026, with FDA CRL response aligned to mid-2027.
Bullish bias into Q4 2026 as traders price higher probability of a registrational path, while near-term focus may shift to upcoming Phase 2 data and FDA end-of-Phase 2 interactions.
The filing is a primary disclosure (8-K with earnings/operations and program milestones) and includes specific timing (APOLLO topline Q4 2026, CRL response mid-2027) and concrete financial runway, which can re-rate biotech risk.
Market effects
Supports risk-on sentiment for hematology-focused clinical-stage biotechs, especially those with heme/iron homeostasis mechanisms and FDA interaction milestones.
Limited direct regional impact; primarily affects US small/mid-cap biotech sentiment.
Moderate, as EHA/ASCO updates and FDA pathway alignment can influence global peer read-across for similar erythropoiesis/iron biology programs.
Counterpoint
Clinical-stage timelines remain uncertain; FDA alignment does not guarantee CRL resolution or successful APOLLO outcomes, so the market may still discount the probability-weighted path.
Key entities
- companyDisc Medicine, Inc.
Clinical-stage biopharmaceutical company focused on hematologic diseases; subject of the 8-K and program milestones.
- programbitopertin (APOLLO, EPP)
GlyT1 inhibitor in erythropoietic protoporphyria; FDA Type A meeting aligned Phase 3 as basis for CRL response, topline expected Q4 2026.
- programselcodebart (RALLY-MF, DISC-0974)
Anti-hemojuvelin antibody in anemia of myelofibrosis; updated Phase 2 data and end-of-Phase 2 FDA interaction expected by year-end.
- programDISC-3405 (RESTORE-PV, PV)
Anti-TMPRSS6 antibody in polycythemia vera; enrollment completed with initial data expected Q3 2026.
